Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Genetic strategy to decrease complement activation with adenoviral therapies.

Gentile CM, Borovjagin AV, Richter JR, Jani AH, Wu H, Zinn KR, Warram JM.

PLoS One. 2019 Apr 26;14(4):e0215226. doi: 10.1371/journal.pone.0215226. eCollection 2019.

2.

B7-H3-targeted radioimmunotherapy of human cancer.

Kasten BB, Ferrone S, Zinn KR, Buchsbaum DJ.

Curr Med Chem. 2019 Feb 28. doi: 10.2174/0929867326666190228120908. [Epub ahead of print]

PMID:
30836909
3.

Radiosynthesis, ex Vivo Biodistribution, and in Vivo Positron Emission Tomography Imaging Evaluations of [11C]2-Pyridinealdoxime Methiodide ([11C]2-PAM): A First-In-Class Antidote Tracer for Organophosphate Intoxication.

Neumann KD, Blecha JE, Hayes TR, Huynh T, Chao CK, Guilloteau N, Zinn KR, VanBrocklin HF, Thompson CM, Gerdes JM.

ACS Chem Neurosci. 2018 Dec 19;9(12):3007-3014. doi: 10.1021/acschemneuro.8b00212. Epub 2018 Aug 20.

4.

Corrigendum to '212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models' [Nucl Med Biol 58 (2018) 67-73].

Kasten BB, Gangrade A, Kim H, Fan J, Ferrone S, Ferrone CR, Zinn KR, Buchsbaum DJ.

Nucl Med Biol. 2018 Jun;61:71. doi: 10.1016/j.nucmedbio.2018.03.004. Epub 2018 Apr 25. No abstract available.

PMID:
29705525
5.

Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells.

Fancy RM, Kim H, Napier T, Buchsbaum DJ, Zinn KR, Song Y.

J Cell Biochem. 2018 Jul;119(7):6216-6230. doi: 10.1002/jcb.26848. Epub 2018 Apr 16.

6.

Translational control of the undifferentiated phenotype in ER‑positive breast tumor cells: Cytoplasmic localization of ERα and impact of IRES inhibition.

Vaklavas C, Zinn KR, Samuel SL, Meng Z, Grizzle WE, Choi H, Blume SW.

Oncol Rep. 2018 Jun;39(6):2482-2498. doi: 10.3892/or.2018.6332. Epub 2018 Mar 23.

7.

212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models.

Kasten BB, Oliver PG, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ.

Int J Mol Sci. 2018 Mar 21;19(4). pii: E925. doi: 10.3390/ijms19040925.

8.

212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models.

Kasten BB, Gangrade A, Kim H, Fan J, Ferrone S, Ferrone CR, Zinn KR, Buchsbaum DJ.

Nucl Med Biol. 2018 Mar;58:67-73. doi: 10.1016/j.nucmedbio.2017.12.004. Epub 2017 Dec 24. Erratum in: Nucl Med Biol. 2018 Apr 25;:.

9.

Subdomain 2, Not the Transmembrane Domain, Determines the Dimerization Partner of Growth Hormone Receptor and Prolactin Receptor.

Liu Y, Jiang J, Lepik B, Zhang Y, Zinn KR, Frank SJ.

Endocrinology. 2017 Oct 1;158(10):3235-3248. doi: 10.1210/en.2017-00469.

10.

Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer.

Rosenthal EL, Moore LS, Tipirneni K, de Boer E, Stevens TM, Hartman YE, Carroll WR, Zinn KR, Warram JM.

Clin Cancer Res. 2017 Aug 15;23(16):4744-4752. doi: 10.1158/1078-0432.CCR-16-2968. Epub 2017 Apr 26.

11.

B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models.

Kasten BB, Arend RC, Katre AA, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ.

Nucl Med Biol. 2017 Apr;47:23-30. doi: 10.1016/j.nucmedbio.2017.01.003. Epub 2017 Jan 10.

12.

Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer Cells.

Fancy RM, Kim H, Zhou T, Zinn KR, Buchsbaum DJ, Song Y.

J Cell Biochem. 2017 Aug;118(8):2285-2294. doi: 10.1002/jcb.25882. Epub 2017 Apr 12.

13.

Oncologic Procedures Amenable to Fluorescence-guided Surgery.

Tipirneni KE, Warram JM, Moore LS, Prince AC, de Boer E, Jani AH, Wapnir IL, Liao JC, Bouvet M, Behnke NK, Hawn MT, Poultsides GA, Vahrmeijer AL, Carroll WR, Zinn KR, Rosenthal E.

Ann Surg. 2017 Jul;266(1):36-47. doi: 10.1097/SLA.0000000000002127. Review.

14.

Effects of an Unlabeled Loading Dose on Tumor-Specific Uptake of a Fluorescently Labeled Antibody for Optical Surgical Navigation.

Moore LS, Rosenthal EL, de Boer E, Prince AC, Patel N, Richman JM, Morlandt AB, Carroll WR, Zinn KR, Warram JM.

Mol Imaging Biol. 2017 Aug;19(4):610-616. doi: 10.1007/s11307-016-1022-1.

15.

A ferret model of COPD-related chronic bronchitis.

Raju SV, Kim H, Byzek SA, Tang LP, Trombley JE, Jackson P, Rasmussen L, Wells JM, Libby EF, Dohm E, Winter L, Samuel SL, Zinn KR, Blalock JE, Schoeb TR, Dransfield MT, Rowe SM.

JCI Insight. 2016 Sep 22;1(15):e87536. doi: 10.1172/jci.insight.87536.

16.

Characterizing the Utility and Limitations of Repurposing an Open-Field Optical Imaging Device for Fluorescence-Guided Surgery in Head and Neck Cancer Patients.

Moore LS, Rosenthal EL, Chung TK, de Boer E, Patel N, Prince AC, Korb ML, Walsh EM, Young ES, Stevens TM, Withrow KP, Morlandt AB, Richman JS, Carroll WR, Zinn KR, Warram JM.

J Nucl Med. 2017 Feb;58(2):246-251. doi: 10.2967/jnumed.115.171413. Epub 2016 Sep 1.

17.

Mice with missense and nonsense NF1 mutations display divergent phenotypes compared with human neurofibromatosis type I.

Li K, Turner AN, Chen M, Brosius SN, Schoeb TR, Messiaen LM, Bedwell DM, Zinn KR, Anastasaki C, Gutmann DH, Korf BR, Kesterson RA.

Dis Model Mech. 2016 Jul 1;9(7):759-67. doi: 10.1242/dmm.025783. Epub 2016 Jun 2.

18.

IRES inhibition induces terminal differentiation and synchronized death in triple-negative breast cancer and glioblastoma cells.

Vaklavas C, Grizzle WE, Choi H, Meng Z, Zinn KR, Shrestha K, Blume SW.

Tumour Biol. 2016 Oct;37(10):13247-13264. Epub 2016 Jul 26.

19.

Imaging, biodistribution, and toxicology evaluation of (212)Pb-TCMC-trastuzumab in nonhuman primates.

Kasten BB, Azure MT, Schoeb TR, Fisher DR, Zinn KR.

Nucl Med Biol. 2016 Jul;43(7):391-6. doi: 10.1016/j.nucmedbio.2016.04.001. Epub 2016 Apr 13.

PMID:
27179247
20.

GHR/PRLR Heteromultimer Is Composed of GHR Homodimers and PRLR Homodimers.

Liu Y, Zhang Y, Jiang J, Lobie PE, Paulmurugan R, Langenheim JF, Chen WY, Zinn KR, Frank SJ.

Mol Endocrinol. 2016 May;30(5):504-17. doi: 10.1210/me.2015-1319. Epub 2016 Mar 22.

21.
22.

Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report.

Rosenthal EL, Warram JM, de Boer E, Basilion JP, Biel MA, Bogyo M, Bouvet M, Brigman BE, Colson YL, DeMeester SR, Gurtner GC, Ishizawa T, Jacobs PM, Keereweer S, Liao JC, Nguyen QT, Olson JM, Paulsen KD, Rieves D, Sumer BD, Tweedle MF, Vahrmeijer AL, Weichert JP, Wilson BC, Zenn MR, Zinn KR, van Dam GM.

J Nucl Med. 2016 Jan;57(1):144-50. doi: 10.2967/jnumed.115.158915. Epub 2015 Oct 8.

23.

Biodistribution Study of Intravenously Injected Cetuximab-IRDye700DX in Cynomolgus Macaques.

de Boer E, Samuel S, French DN, Warram JM, Schoeb TR, Rosenthal EL, Zinn KR.

Mol Imaging Biol. 2016 Apr;18(2):232-42. doi: 10.1007/s11307-015-0892-y.

PMID:
26335283
24.

Small molecule inhibitors of IRES-mediated translation.

Vaklavas C, Meng Z, Choi H, Grizzle WE, Zinn KR, Blume SW.

Cancer Biol Ther. 2015;16(10):1471-85. doi: 10.1080/15384047.2015.1071729. Epub 2015 Jul 15.

25.

In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas.

de Boer E, Warram JM, Tucker MD, Hartman YE, Moore LS, de Jong JS, Chung TK, Korb ML, Zinn KR, van Dam GM, Rosenthal EL, Brandwein-Gensler MS.

Sci Rep. 2015 Jun 29;5:10169. doi: 10.1038/srep10169.

26.

Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer.

Rosenthal EL, Warram JM, de Boer E, Chung TK, Korb ML, Brandwein-Gensler M, Strong TV, Schmalbach CE, Morlandt AB, Agarwal G, Hartman YE, Carroll WR, Richman JS, Clemons LK, Nabell LM, Zinn KR.

Clin Cancer Res. 2015 Aug 15;21(16):3658-66. doi: 10.1158/1078-0432.CCR-14-3284. Epub 2015 Apr 22.

27.

Salutary Effects of Estrogen Sulfate for Traumatic Brain Injury.

Kim H, Cam-Etoz B, Zhai G, Hubbard WJ, Zinn KR, Chaudry IH.

J Neurotrauma. 2015 Aug 15;32(16):1210-6. doi: 10.1089/neu.2014.3771. Epub 2015 Apr 22.

28.

The status of contemporary image-guided modalities in oncologic surgery.

Rosenthal EL, Warram JM, Bland KI, Zinn KR.

Ann Surg. 2015 Jan;261(1):46-55. doi: 10.1097/SLA.0000000000000622. Review.

29.

Synthesis and biological evaluation of panitumumab-IRDye800 conjugate as a fluorescence imaging probe for EGFR-expressing cancers.

Bhattacharyya S, Patel N, Wei L, Riffle LA, Kalen JD, Hill GC, Jacobs PM, Zinn KR, Rosenthal E.

Medchemcomm. 2014 Sep;5(9):1337-1346.

30.

The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts.

Nelson CA, Azure MT, Adams CT, Zinn KR.

J Nucl Med. 2014 Dec;55(12):2020-5. doi: 10.2967/jnumed.114.140780. Epub 2014 Oct 30.

31.

Human GH receptor-IGF-1 receptor interaction: implications for GH signaling.

Gan Y, Buckels A, Liu Y, Zhang Y, Paterson AJ, Jiang J, Zinn KR, Frank SJ.

Mol Endocrinol. 2014 Nov;28(11):1841-54. doi: 10.1210/me.2014-1174. Epub 2014 Sep 11. Erratum in: Mol Endocrinol. 2015 Feb;29(2):332.

32.

Dynamic analysis of GH receptor conformational changes by split luciferase complementation.

Liu Y, Berry PA, Zhang Y, Jiang J, Lobie PE, Paulmurugan R, Langenheim JF, Chen WY, Zinn KR, Frank SJ.

Mol Endocrinol. 2014 Nov;28(11):1807-19. doi: 10.1210/me.2014-1153. Epub 2014 Sep 4.

33.

Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer.

Kim H, Samuel SL, Zhai G, Rana S, Taylor M, Umphrey HR, Oelschlager DK, Buchsbaum DJ, Zinn KR.

Cancer Biol Ther. 2014 Aug;15(8):1053-60. doi: 10.4161/cbt.29183.

34.

IND-directed safety and biodistribution study of intravenously injected cetuximab-IRDye800 in cynomolgus macaques.

Zinn KR, Korb M, Samuel S, Warram JM, Dion D, Killingsworth C, Fan J, Schoeb T, Strong TV, Rosenthal EL.

Mol Imaging Biol. 2015 Feb;17(1):49-57. doi: 10.1007/s11307-014-0773-9.

35.

A dual-reporter, diagnostic vector for prostate cancer detection and tumor imaging.

Richter JR, Mahoney M, Warram JM, Samuel S, Zinn KR.

Gene Ther. 2014 Oct;21(10):897-902. doi: 10.1038/gt.2014.68. Epub 2014 Jul 24.

36.

Biodistribution of P-selectin targeted microbubbles.

Warram JM, Sorace AG, Mahoney M, Samuel S, Harbin B, Joshi M, Martin A, Whitworth L, Hoyt K, Zinn KR.

J Drug Target. 2014 Jun;22(5):387-94. doi: 10.3109/1061186X.2013.869822. Epub 2014 Apr 14.

37.

Ultrasound-stimulated drug delivery for treatment of residual disease after incomplete resection of head and neck cancer.

Sorace AG, Korb M, Warram JM, Umphrey H, Zinn KR, Rosenthal E, Hoyt K.

Ultrasound Med Biol. 2014 Apr;40(4):755-64. doi: 10.1016/j.ultrasmedbio.2013.11.002. Epub 2014 Jan 10.

38.

Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer.

Korb ML, Hartman YE, Kovar J, Zinn KR, Bland KI, Rosenthal EL.

J Surg Res. 2014 May 1;188(1):119-28. doi: 10.1016/j.jss.2013.11.1089. Epub 2013 Nov 22.

39.

Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopy.

Zhai G, Kim H, Sarver D, Samuel S, Whitworth L, Umphrey H, Oelschlager DK, Beasley TM, Zinn KR.

J Magn Reson Imaging. 2014 Jun;39(6):1588-94. doi: 10.1002/jmri.24319. Epub 2013 Oct 22.

40.

Enhancement of adenovirus delivery after ultrasound-stimulated therapy in a cancer model.

Sorace AG, Warram JM, Mahoney M, Zinn KR, Hoyt K.

Ultrasound Med Biol. 2013 Dec;39(12):2374-81. doi: 10.1016/j.ultrasmedbio.2013.07.017. Epub 2013 Sep 21.

41.

A novel extracellular drug conjugate significantly inhibits head and neck squamous cell carcinoma.

Sweeny L, Hartman YE, Zinn KR, Prudent JR, Marshall DJ, Shekhani MS, Rosenthal EL.

Oral Oncol. 2013 Oct;49(10):991-7. doi: 10.1016/j.oraloncology.2013.07.006. Epub 2013 Aug 3.

42.

Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers.

Kim H, Rigell CJ, Zhai G, Lee SK, Samuel SL, Martin A, Umphrey HR, Stockard CR, Beasley TM, Buchsbaum DJ, Li LS, Boothman DA, Zinn KR.

Mol Imaging Biol. 2014 Feb;16(1):85-94. doi: 10.1007/s11307-013-0665-4. Epub 2013 Jul 9.

43.

Putting numbers to fluorescent guided surgery.

Rosenthal EL, Zinn KR.

Mol Imaging Biol. 2013 Dec;15(6):647-8. doi: 10.1007/s11307-013-0662-7.

PMID:
23836503
44.

Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma.

Day KE, Sweeny L, Kulbersh B, Zinn KR, Rosenthal EL.

Mol Imaging Biol. 2013 Dec;15(6):722-9. doi: 10.1007/s11307-013-0652-9.

45.

Fluorescently labeled therapeutic antibodies for detection of microscopic melanoma.

Day KE, Beck LN, Deep NL, Kovar J, Zinn KR, Rosenthal EL.

Laryngoscope. 2013 Nov;123(11):2681-9. doi: 10.1002/lary.24102. Epub 2013 Apr 24.

46.

Use of panitumumab-IRDye800 to image cutaneous head and neck cancer in mice.

Heath CH, Deep NL, Beck LN, Day KE, Sweeny L, Zinn KR, Huang CC, Rosenthal EL.

Otolaryngol Head Neck Surg. 2013 Jun;148(6):982-90. doi: 10.1177/0194599813482290. Epub 2013 Mar 22.

47.

Optical fluorescent imaging to monitor temporal effects of microbubble-mediated ultrasound therapy.

Sorace AG, Saini R, Rosenthal E, Warram JM, Zinn KR, Hoyt K.

IEEE Trans Ultrason Ferroelectr Freq Control. 2013 Feb;60(2):281-9. doi: 10.1109/TUFFC.2013.2564.

48.

Identification of the optimal therapeutic antibody for fluorescent imaging of cutaneous squamous cell carcinoma.

Day KE, Beck LN, Heath CH, Huang CC, Zinn KR, Rosenthal EL.

Cancer Biol Ther. 2013 Mar;14(3):271-7. doi: 10.4161/cbt.23300. Epub 2013 Jan 8.

49.

An animal model allowing controlled receptor expression for molecular ultrasound imaging.

Saini R, Sorace AG, Warram JM, Mahoney MJ, Zinn KR, Hoyt K.

Ultrasound Med Biol. 2013 Jan;39(1):172-80. doi: 10.1016/j.ultrasmedbio.2012.08.016. Epub 2012 Nov 2.

50.

Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model.

Heath CH, Deep NL, Sweeny L, Zinn KR, Rosenthal EL.

Ann Surg Oncol. 2012 Nov;19(12):3879-87. doi: 10.1245/s10434-012-2435-y. Epub 2012 Jun 6.

Supplemental Content

Support Center